Healthcare / Diagnostics & ResearchShenzhen
$9.15
-0.14 (-1.51%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $75.2M · quality 61.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.5B
P/E
53.8x
↑EV/EBITDA
13.6x
↑ROE
2.1%
↑Gross Margin
36.8%
↓Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-14.8%
FCF CAGR
-34.0%
FCF margin
4.9%
FCF / Net income
1.19x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.54B · net income $63.2M · FCF $75.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.54B | $1.54B | $1.74B | $1.89B | $2.49B |
| Net Income | $63.2M | $63.2M | $258.0M | $256.6M | $198.5M |
| EBITDA | $221.5M | $221.5M | $495.1M | $476.0M | $430.6M |
| EPS | 0.16 | 0.16 | 0.67 | 0.67 | 0.52 |
| Gross Margin | 36.8% | 36.8% | 44.6% | 44.1% | 38.2% |
| Operating Margin | 4.0% | 4.0% | 14.1% | 13.4% | 12.6% |
| Net Margin | 4.1% | 4.1% | 14.8% | 13.6% | 8.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.03 | 0.03 | 0.13 |
| Current Ratio | 3.46 | 3.46 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $75.2M | $75.2M | $-22.7M | $353.2M | $261.5M |
| Returns | |||||
| ROE | 2.1% | 2.1% | 8.8% | 9.4% | 7.9% |
| Valuation | |||||
| P/E | 53.82 | 53.82 | 14.85 | 17.28 | 22.96 |
| EV/EBITDA | 13.62 | 13.62 | 6.43 | 7.50 | 9.48 |
| P/B | 1.22 | 1.22 | 1.30 | 1.63 | 1.82 |
| Growth & Yield | |||||
| Revenue Growth | -11.7% | -11.7% | -7.6% | -24.2% | — |
| EPS Growth | -76.1% | -76.1% | 0.0% | 28.8% | — |
| Dividend Yield | 1.5% | 1.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
71.8%
EPS terminal req.
$0.81
Spread vs growth
-148.0%
5Y implied EPS CAGR
43.8%
EPS terminal req.
$0.98
Spread vs growth
-119.9%
10Y implied EPS CAGR
25.8%
EPS terminal req.
$1.58
Spread vs growth
-101.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-10.7%
Start / end P/E
15.5x → 57.2x
EPS bridge
0.67 → 0.16
Residual
-204.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.